Shoulder Innovations commenced full commercial launch of the InSet 70 Humeral Stem, an expansion of the company’s I-Series humeral stem product line, which first launched with the InSet 95 humeral stem in 2024.
Indicated for use in both anatomic and reverse shoulder arthroplasty, InSet 70 addresses a range of clinical needs, including non-inflammatory degenerative joint disease such as osteoarthritis and avascular necrosis, rheumatoid and traumatic arthritis, and correction of functional deformity. In reverse procedures, it is further indicated for irreparable cuff tears with or without arthritis, as well as for revision of other devices when sufficient bone stock remains.
“The InSet 70 complements our broad portfolio of advanced shoulder implant solutions, and we are excited to bring it to market across the United States ahead of schedule,” said Rob Ball, CEO of Shoulder Innovations. “SI has a strong history of innovation, and the InSet 70 is another example of new technology designed to enhance the quality of care for patients and provide meaningful value to the surgeons who care for them. We look forward to seeing improved patient outcomes and long-term function with this implant.”
Shoulder Innovations commenced full commercial launch of the InSet 70 Humeral Stem, an expansion of the company's I-Series humeral stem product line, which first launched with the InSet 95 humeral stem in 2024.
Indicated for use in both anatomic and reverse shoulder arthroplasty, InSet 70 addresses a range of clinical needs, including...
Shoulder Innovations commenced full commercial launch of the InSet 70 Humeral Stem, an expansion of the company’s I-Series humeral stem product line, which first launched with the InSet 95 humeral stem in 2024.
Indicated for use in both anatomic and reverse shoulder arthroplasty, InSet 70 addresses a range of clinical needs, including non-inflammatory degenerative joint disease such as osteoarthritis and avascular necrosis, rheumatoid and traumatic arthritis, and correction of functional deformity. In reverse procedures, it is further indicated for irreparable cuff tears with or without arthritis, as well as for revision of other devices when sufficient bone stock remains.
“The InSet 70 complements our broad portfolio of advanced shoulder implant solutions, and we are excited to bring it to market across the United States ahead of schedule,” said Rob Ball, CEO of Shoulder Innovations. “SI has a strong history of innovation, and the InSet 70 is another example of new technology designed to enhance the quality of care for patients and provide meaningful value to the surgeons who care for them. We look forward to seeing improved patient outcomes and long-term function with this implant.”
Copy to clipboard 
